NASDAQ:GLPGGALAPAGOS NV/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GALAPAGOS NV/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $202.78 +1.31 (+0.65 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$201.44Now: $202.78▼$207.9850-Day Range$197.79MA: $212.86▼$231.2552-Week Range$112.00Now: $202.78▼$274.03Volume218,607 shsAverage Volume176,464 shsMarket Capitalization$13.14 billionP/E Ratio79.83Dividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingGALAPAGOS NV/S has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 7 buy ratings, 7 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $229.00, GALAPAGOS NV/S has a potential upside of 12.9% from its current price of $202.78.Amount of Analyst CoverageGALAPAGOS NV/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesGALAPAGOS NV/S has received 427 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGALAPAGOS NV/S has received 369 “underperform” votes. (Add your “underperform” vote.)Community SentimentGALAPAGOS NV/S has received 53.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote “Outperform” if you believe GLPG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGALAPAGOS NV/S does not currently pay a dividend.Dividend GrowthGALAPAGOS NV/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GALAPAGOS NV/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of GALAPAGOS NV/S is held by insiders.Percentage Held by InstitutionsOnly 11.71% of the stock of GALAPAGOS NV/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GALAPAGOS NV/S are expected to decrease in the coming year, from ($1.71) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GALAPAGOS NV/S is 79.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.35.Price to Earnings Ratio vs. SectorThe P/E ratio of GALAPAGOS NV/S is 79.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.26.Price to Book Value per Share RatioGALAPAGOS NV/S has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG Previous Symbol CUSIPN/A CIK1421876 Webwww.glpg.com Phone321-534-2900Debt Debt-to-Equity Ratio0.01 Current Ratio9.28 Quick Ratio9.28Price-To-Earnings Trailing P/E Ratio79.83 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.00 billion Price / Sales13.10 Cash Flow$6.40 per share Price / Cash Flow31.66 Book Value$48.34 per share Price / Book4.19Profitability EPS (Most Recent Fiscal Year)$5.46 Net Income$167.83 million Net Margins15.42% Return on Equity12.45% Return on Assets6.07%Miscellaneous Employees1,003 Outstanding Shares64,820,000Market Cap$13.14 billion Next Earnings Date7/23/2020 (Estimated) OptionableOptionable NASDAQ:GLPG Rates by TradingView Receive GLPG News and Ratings via Email Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions How has GALAPAGOS NV/S's stock been impacted by COVID-19 (Coronavirus)? GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GLPG shares have increased by 9.0% and is now trading at $202.78. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of GALAPAGOS NV/S? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GALAPAGOS NV/S. When is GALAPAGOS NV/S's next earnings date? GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for GALAPAGOS NV/S. How were GALAPAGOS NV/S's earnings last quarter? GALAPAGOS NV/S (NASDAQ:GLPG) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. The biotechnology company had revenue of $117.93 million for the quarter, compared to the consensus estimate of $121.39 million. GALAPAGOS NV/S had a return on equity of 12.45% and a net margin of 15.42%. View GALAPAGOS NV/S's earnings history. What price target have analysts set for GLPG? 16 Wall Street analysts have issued 12-month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $155.00 to $298.00. On average, they expect GALAPAGOS NV/S's share price to reach $229.00 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View analysts' price targets for GALAPAGOS NV/S. Has GALAPAGOS NV/S been receiving favorable news coverage? News stories about GLPG stock have trended extremely negative on Friday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutGALAPAGOS NV/S. Who are some of GALAPAGOS NV/S's key competitors? Some companies that are related to GALAPAGOS NV/S include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Catalent (CTLT). View all competitors. What other stocks do shareholders of GALAPAGOS NV/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), argenx (ARGX), NVIDIA (NVDA), AbbVie (ABBV), Pharming Group (PHGUF), Trade Desk (TTD), Biogen (BIIB) and Collegium Pharmaceutical (COLL). Who are GALAPAGOS NV/S's key executives? GALAPAGOS NV/S's management team includes the following people: Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)Mr. Bart Filius MBA, CFO & COO (Age 49)Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. CommunicationsDr. Andre Hoekema, Chief Bus. Officer (Age 62) When did GALAPAGOS NV/S IPO? (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. What is GALAPAGOS NV/S's stock symbol? GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG." Who are GALAPAGOS NV/S's major shareholders? GALAPAGOS NV/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (3.44%), Federated Hermes Inc. (2.17%), BlackRock Inc. (0.49%), Bessemer Group Inc. (0.36%), Wellington Management Group LLP (0.20%) and Morgan Stanley (0.19%). Which major investors are selling GALAPAGOS NV/S stock? GLPG stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Wellington Management Group LLP, Federated Hermes Inc., Jane Street Group LLC, Bessemer Group Inc., Public Employees Retirement Association of Colorado, Wealth Quarterback LLC, and Peregrine Capital Management LLC. Which major investors are buying GALAPAGOS NV/S stock? GLPG stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, United Capital Financial Advisers LLC, Envestnet Asset Management Inc., and Parametric Portfolio Associates LLC. How do I buy shares of GALAPAGOS NV/S? Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GALAPAGOS NV/S's stock price today? One share of GLPG stock can currently be purchased for approximately $202.78. How big of a company is GALAPAGOS NV/S? GALAPAGOS NV/S has a market capitalization of $13.14 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe. What is GALAPAGOS NV/S's official website? The official website for GALAPAGOS NV/S is www.glpg.com. How can I contact GALAPAGOS NV/S? GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
